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Abstract
Following traumatic brain injury (TBI) neurological damage is ongoing through a complex
cascade of primary and secondary injury events in the ensuing minutes, days and weeks.
The delayed nature of secondary injury provides a valuable window of opportunity to limit
the consequences with a timely treatment. Recently, the amyloid precursor protein (APP)
and its derivative APP96-110 have shown encouraging neuroprotective activity following
TBI following an intracerebroventricular administration. Nevertheless, its broader clinical
utility would be enhanced by an intravenous (IV) administration. This study assessed the
efficacy of IV APP96-110, where a dose-response for a single dose of 0.005mg/kg– 0.5mg/
kg APP96-110 at either 30 minutes or 5 hours following moderate-severe diffuse impact-
acceleration injury was performed. Male Sprague-Dawley rats were assessed daily for 3 or
7 days on the rotarod to examine motor outcome, with a separate cohort of animals utilised
for immunohistochemistry analysis 3 days post-TBI to assess axonal injury and neuroinflam-
mation. Animals treated with 0.05mg/kg or 0.5mg/kg APP96-110 after 30 minutes demon-
strated significant improvements in motor outcome. This was accompanied by a reduction
in axonal injury and neuroinflammation in the corpus callosum at 3 days post-TBI, whereas
0.005mg/kg had no effect. In contrast, treatment with 0.005m/kg or 0.5mg/kg APP96-110 at
5 hours post-TBI demonstrated significant improvements in motor outcome over 3 days,
which was accompanied by a reduction in axonal injury in the corpus callosum. This demon-
strates that APP96-110 remains efficacious for up to 5 hours post-TBI when administered
IV, and supports its development as a novel therapeutic compound following TBI.
Introduction
Traumatic brain injury (TBI) is a major public health concern, one which in industrialised
countries leads to more deaths in people under the age of 45 than any other cause [1].
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Following TBI, extensive neurological damage occurs through the initiation of multiple injury
events, both immediately after and progressively from the initial injury. This delayed injury is
a prolonged and deleterious cascade of cellular and biochemical events that often compound
the existing injury including excitotoxicity, oxidative stress, irreversible cell injury and death,
inflammation and blood-brain-barrier (BBB) disruption [2–5]. Diffuse axonal injury (DAI), a
significant feature of TBI, is the most common cause of coma and vegetative state following
head trauma [6, 7]. Occurring as a result of rapid acceleration/deceleration forces, DAI causes
considerable deformation of brain tissue through shearing forces and stretching, and currently
lacks an efficacious pharmacological treatment. Many of these serious events could be reversed
if targeted with an appropriate therapy, preventing serious complications and reducing the
burden on society. Fortunately, the delayed onset and potentially reversible nature of these sec-
ondary events provides a novel window of opportunity for a therapy to reduce neuronal dam-
age and help limit the associated morbidity and mortality of TBI [3]. It has been proposed that
upcoming therapeutic interventions should be multifactorial in nature and target multiple ele-
ments of the secondary injury cascade [3, 8, 9]. One frequently proposed approach is to emu-
late the brain’s endogenous repair response.
It has been consistently demonstrated that the amyloid precursor protein (APP) and its
derivatives are neuroprotective following experimental TBI [10–14]. Intracerebroventricular
administration of APP was shown to ameliorate both motor and cognitive deficits, as well as
attenuate cellular loss and inflammation following TBI in vivo. This makes APP a promising
candidate to develop as a therapeutic treatment for TBI patients. APP undergoes distinct pro-
teolytic events [15], and the soluble APPα (sAPPα) species, produced via proteolytic cleavage
with α-secretase enzyme, is thought to be responsible for APP’s neuroprotective properties fol-
lowing TBI, including protection against a range of cytotoxic insults, regulation of neurite out-
growth and synaptogenesis, and improvement in functional outcome in vivo [16–18]. Domain
mapping studies attributed the neuroprotective activity of sAPPα to the growth factor domains
[11], with subsequent sequence activity studies able to localize the neuroprotective activity to
the N-terminal heparin binding region, encompassed by amino acid residues 96–110 [14]. It
was shown that APP96-110’s neuroprotective activity correlated with its affinity for heparin
[11, 14, 19]. Intracerebroventricular administration of APP96-110 was shown to not only
restore motor and cognitive deficits, but also preserve cortical and hippocampal tissue in
APP-/- mice, and reduce axonal injury in the corpus callosum following diffuse TBI in rats.
This suggests that that APP96-110 could functionally substitute for native sAPPα [14].
Whilst these results using intracerebroventricular administration are promising and clini-
cally relevant, the intravenous (IV) route of administration would provide a more tractable
method of drug administration, especially in a paramedic setting where TBI victims will first
encounter medical treatment. Accordingly, this study aimed to determine the efficacy of IV
administered APP96-110, along with its therapeutic window, following moderate-severe dif-
fuse TBI. APP96-110 was firstly administered IV at 30 minutes after trauma, and its effects on
motor outcome, the extent of DAI and neuroinflammation at 3 days were assessed. Secondly,
delayed IV administration of APP96-110 at 5 hours post-TBI was assessed to determine if
APP96-110 would remain efficacious at a delayed but more clinically relevant time point.
Methods
All studies were performed within the guidelines established by the National Health and Medi-
cal Research Committee of Australia and were approved by the Animal Ethics Committee of
the University of Adelaide. All animals were purchased from the University of Adelaide breed-
ing facility.
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The APP96-110 peptide
The APP96-110 peptide, NWCKRGRKQCKTHPH, was synthesized by Auspep (Tullamarine,
Victoria, Australia) and was N-terminally acetylated and C-terminally amidated. The peptide
was dissolved into distilled water to produce a 1mM stock solution, and further diluted to pro-
duce doses of 0.5mg/kg and 0.05mg/kg APP96-110.
Evaluation of the efficacy of IV APP96-110 administered at 30 minutes
following TBI
Injury induction. A total of 62 adult male Sprague-Dawley rats weighing between 336g
and 427g were group housed in a controlled temperature environment under a 12 hour light/
dark cycle, with uninterrupted access to food and water. Animals were randomly assigned into
3 day histological and 7 day outcome groups, and each further assigned into sham, vehicle con-
trol, 0.005mg/kg, 0.05mg/kg and 0.5mg/kg APP96-110 treatment groups.
Animals were injured using the impact-acceleration model of diffuse TBI [20]. This injury
model produces a rage of injuries from moderate through to moderate–severe, and its hetero-
geneity provides a clinically relevant model to test neuroprotective therapeutics. Animals were
anesthetized with isoflurane and upon the absence of pain reflexes, a midline incision was
made on the skull, a metallic disk (10mm in diameter and 3mm in depth) was adhered onto
the skull centrally between lambda and bregma sutures. Animals were placed on a foam bed of
10cm height, and injured by releasing a 450g weight from 2 meters onto the metallic disk [20].
The model of TBI is associated with a period of apnea in unventilated animals. To regulate this
and replicate what occurs clinically, animals were ventilated directly after injury whilst intro-
ducing a period of post-traumatic hypoxia with 2L/min of nitrogen and 0.2L/min of oxygen
[21]. Post-traumatic hypoxia has been previously shown to exacerbate both axonal injury and
inflammation, and can often be attributed to poor neurological outcome post-TBI [21]. Sham
animals were surgically prepared but not injured and did not receive hypoxia. The use of gen-
eral anaesthetics and the absence of pain receptors in the brain means injury to the brain tissue
is not painful for the animals. However, the initial skin incision on the scalp required to adhere
the metallic disk can cause minor discomfort in the initial 24 hours post-surgery. As such, all
animals received 0.2mL subcutaneous Lignocaine under the incision site at the end of the pro-
cedure to minimize pain and discomfort.
At 30 minutes following TBI, animals were administered either saline, 0.005mg/kg,
0.05mg/kg or 0.5mg/kg APP96-110 intravenously via the tail vein by a blinded observer, and
returned to their home cage to recover once normal behaviour was established. Intensive con-
tinuous monitoring of the animals was provided for the first 2 hours post-procedure and ani-
mals were then checked at least hourly for the next 4 hours. If signs of clinical deterioration
were evident, the frequency of monitoring was adjusted accordingly so that appropriate inter-
vention could occur. Following this initial period, animals were monitored twice daily with
clinical record sheets maintained to assess the following criteria: daily weight loss, appearance
and texture of their coats, posture, changes in social behaviour, as well as the presence or
absence of stress marks, circling behaviour, OP site swelling, and paresis. Weight loss of greater
than 5–10% of their pre-surgical body weight were treated with subcutaneous saline to prevent
dehydration. Overall, 9 animals died shortly following the trauma, with a further 9 animals
euthanized prior to the end of experiments in accordance with ethical guidelines.
Assessment of motor outcome. Motor deficits post-TBI were assessed using the rotarod,
a sensitive test of motor ability following TBI [22]. Briefly, the rotarod comprises of 18 rotating
metallic rods on which the animal is required to balance and walk. The speed of the rotarod is
increased from 6 to 36 rpm in intervals of by 3 rpm every 10 seconds. Animals were pre-
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trained daily on the rotarod for 5 days until they could complete 120 seconds, and were then
assessed daily for 7 days post-injury. The length of time in seconds that animals were success-
fully able to walk on the rotarod post-injury was recorded.
Histological assessment. At 3 days post-TBI, animals were anaesthetized with isoflur-
ane, and upon the absence of pain reflexes, were transcardially perfused with 10% formalin.
Animals were perfused at 3 days rather than 7, as the most significant improvements in
motor outcome were observed within the first 3 days following trauma. Fixed brains were
sectioned into 2mm coronal slices and embedded in paraffin wax, before the brain region
containing the area under the impact (-0.40mm relative to Bregma) was further sectioned
into 5μm coronal slices for representative serial sections. Immunohistochemistry was per-
formed following standard procedure with sections stained for APP for axonal injury
(22C11; Boe´hringer, 1:1000), glial fibrillary acidic protein (GFAP; Dako, 1:40,000) and Iba1
(Wako, 1:10,000). Following overnight incubation with the primary antibody, slides were
then incubated with the appropriate secondary antibody (1:250, Vector), before incubation
with streptavidin peroxidase conjugate (SPC—1:1000). This was followed by antigen detec-
tion with 3,30-Diaminobenzidine tetrahydrochloride (DAB) for 7 minutes, and sections
counterstained with haematoxylin. Sections were digitally scanned using the Nanozoomer
slide scanner (Hamamatsu, Hamamatusu City, Shizuoka, Japan), and the associated software
(NDPview) used to view and analyze the images. The extent of DAI was assessed by counting
the number of APP immunopositive (APP+) lengths in the entire length of the corpus callo-
sum (from left to right) of two consecutive brain sections per animal, where each animal rep-
resents a 10μm area of the corpus callosum. This area is directly under the impact site
(-0.40mm relative to Bregma), and was chosen as this region has previously demonstrated
the highest degree of axonal injury.
GFAP and Iba1 immunoreactivity was determined by assessing morphology (Fig 1). Reac-
tive astrocytes differ from other astrocytes through the increased GFAP expression surround-
ing the cell body, giving the appearance of a thick and dark halo-like appearance.
Furthermore, their processes become shorter, thicker and darker than those of their unreactive
counterparts. Conversely, activated microglia can exhibit a number of different morphological
characteristics, including changes to the size of the cell body and processes. Microglia demon-
strating an increase in length, number and thickness of their processes were of most impor-
tance for this study. The number of reactive astrocytes and activated microglia were counted
within the same region of the corpus callosum of two consecutive brains sections per animal,
Fig 1. Representative images showing the morphological differences between astrocytes (a) and microglia (b) in the corpus
callosum. Astrocytes (a) are characterized morphologically into non-reactive (A) and reactive (B) astrocytes, while microglia (b) are
characterized morphologically into inactivated (A) and activated (B) microglia.
https://doi.org/10.1371/journal.pone.0190449.g001
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as with APP histology. All histological counts were done blinded by two assessors using strict
criteria, and minimal inter-observer variation was found.
Evaluation of the efficacy of IV APP96-110 administered at 5 hours
following TBI
A total of 40 adult male Sprague-Dawley rats weighing between 361g and 427g were randomly
assigned into 3 day sham, vehicle control, 0.05mg/kg and 0.5mg/kg APP96-110 treatment
groups. The APP96-110 peptide was manufactured as described above, and animals were
again injured using the impact-acceleration model of diffuse TBI as described above [20]. 4
animals died shortly following the trauma, with the remaining animals monitored appropri-
ately in accordance with ethical guidelines as previously described. Sham animals were surgi-
cally prepared but not injured. At 5 hours following TBI, animals were administered either
saline, 0.05mg/kg or 0.5mg/kg APP96-110 intravenously via the tail vein by a blinded observer,
before being returned to their home cage to recover once normal behaviour was established.
Motor outcome and histological assessments were carried out as previously described.
Statistical analysis. All data were analyzed using Graph Pad Prism software. All values
are displayed as Mean ± SEM, with a significance level of p<0.05. Motor outcome was assessed
using a two-way repeated measures ANOVA with Tukey’s post-test. DAI and the number of
reactive astrocytes and activated microglia were by assessed using a one-way ANOVA with
Tukey’s post-test.
Results
Examining the efficacy of IV APP96-110 administered at 30 minutes
following TBI
Administration of APP96-110 was efficacious on motor outcome. Motor outcome
post-TBI was assessed using the rotarod (Fig 2). Sham animals (n = 7) demonstrated normal
motor abilities over the testing period, recording 120 seconds on all 7 days post-injury. In con-
trast, vehicle control animals showed significant motor deficits when compared to shams on
days 1 to 3 post-TBI (p<0.01, n = 9). Animals treated with 0.005mg/kg APP96-110 (n = 9) per-
formed similarly to vehicles, and were significantly different to shams on days 1 to 4 post-
injury (p<0.05). However, treatment with both 0.05mg/kg (n = 9) and 0.5mg/kg (n = 7)
APP96-110 improved motor outcome over 7 days, as these animals only recorded significant
motor deficits different to sham animals on days 1 and 2 post-injury (p<0.05).
APP96-110 administration after TBI reduced axonal injury. The finding that only the
0.05mg/kg and 0.5mg/kg doses of APP96-110 were able to significantly improve motor out-
come, led us to analyze these doses in histological studies for axonal injury and neuroinflam-
mation at 3 days post-TBI.
The extent of DAI was determined by counting the number of APP immunopositive
lengths within the corpus callosum at 3 days post-TBI (Fig 3). APP is a robust marker for
assessing axonal injury [23]. A significant increase in APP immunoreactivity was observed in
vehicle control animals at 3 days post-TBI (161±19, p<0.001, n = 4)) when compared to sham
animals (p<0.001, n = 5). Administration of both doses of APP96-110 showed a reduction in
DAI post-TBI, however, a significant reduction compared to vehicle animals was only
recorded in the 0.05mg/kg dose (79±19, p<0.05, n = 5), and not the 0.5mg/kg dose (124±21,
n = 4).
APP96-110 administration after TBI reduced neuroinflammation. Neuroinflammation
was assessed by counting the number of reactive astrocytes and activated microglia within the
IV APP96-110 improves outcome after TBI
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corpus callosum at 3 days post-TBI (Figs 4 & 5). GFAP immunoreactivity (Fig 4) demonstrated
a significant increase in the number of reactive astrocytes within the corpus callosum in vehicle
control animals (243±11, n = 5) at 3 days post-TBI when compared to sham animals (174±10,
p<0.01, n = 4). Treatment with both 0.05mg/kg (n = 5) and 0.5mg/kg (n = 4) doses of APP96-
110 demonstrated significant reductions in GFAP immunoreactivity (170±9 and 172±6,
respectively), compared to vehicle control animals (p<0.001), with levels similar to that seen
in shams.
These astrocytic changes were mirrored by Iba1 immunoreactivity (Fig 5) where a signifi-
cant increase in the number of microglia was observed in the corpus callosum of vehicle con-
trol animals (127±7, n = 5) at 3 days post-TBI when compared to sham animals (85±4, p<0.01,
n = 4). Notably, animals treated with both the 0.05mg/kg (n = 5) and 0.5mg/kg (n = 4) doses of
APP96-110 also demonstrated a return to sham level, with significant reductions in the num-
ber of activated microglia in both treatment groups, 92±4 and 82±1, respectively (p<0.001),
when compared to vehicle control animals.
Evaluation of the efficacy of IV APP96-110 administered at 5 hours
following TBI
In order to determine whether IV APP96-110 would remain efficacious if delivered at a later
and more clinically relevant time point, injured rats were injected 5 hours post-TBI. Rats were
treated with either 0.05mg/kg or 0.5mg/kg APP96-110, as these doses were efficacious as deter-
mined above.
Fig 2. Motor outcome illustrating the effect of treatment with 0.005mg/kg, 0.05mg/kg and 0.5mg/kg APP96-110
IV at 30 minutes post-TBI. Data were assessed with a two-way repeated measures ANOVA followed by Tukey’s post-
test. (Sham n = 7, vehicle n = 9, 0.005mg/kg n = 9, 0.05mg/kg n = 9, 0.05mg/kg n = 7, per group). (p<0.001,
p<0.01, p<0.05, compared to sham animals).
https://doi.org/10.1371/journal.pone.0190449.g002
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Delayed administration of APP96-110 remained efficacious on motor outcome. As
motor deficits were most pronounced on days 1 to 3 post-injury (Fig 2), motor outcome was
assessed on these days (Fig 6). Sham animals (n = 7) demonstrated normal motor abilities over
the 3 day testing period, recording 120 seconds on all 3 days post-injury, whereas vehicle con-
trol animals demonstrated significant motor deficits when compared to shams on all 3
Fig 3. Representative images showing the degree of DAI in the corpus callosum at 3 days following diffuse TBI (a-d). 0.05mg/kg (c)
and 0.5mg/kg (d) APP960110 treated animals demonstrated a reduced number of APP immunopositive lengths in the corpus callosum at 3
days following injury, compared to vehicle treated animals (b), with 0.05mg/kg APP96-110 treated animals showing the most pronounced
reduction. These observations were confirmed with counts of the number of APP immunopositive lengths (e). APP+ lengths were assessed
using a one-way ANOVA followed by Tukey’s post-test. (Sham n = 5, vehicle n = 4, 0.05mg/kg n = 5, 0.5mg/kg n = 4) (p<0.05, compared
to vehicle control animals).
https://doi.org/10.1371/journal.pone.0190449.g003
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assessment days (p<0.001, n = 9). In contrast, treatment with both doses of APPP96-110 sig-
nificantly improved motor ability. Animals treated with 0.05mg/kg APP96-110 (p<0.01,
n = 10) or 0.5mg/kg APP96-110 (p<0.001, n = 10) demonstrated significant improvements in
motor outcome compared to vehicle animals on all 3 days following TBI. (p<0.01). There
were no significant differences between the two APP96-110 doses.
Fig 4. Representative images showing the degree of neuroinflammation in the corpus callosum at 3 days following diffuse TBI, as
assessed by GFAP immunoreactivity (a-d). 0.05mg/kg (c) and 0.5mg/kg (d) APP96-110 treated animals demonstrated a clear reduction
in the number of reactive astrocytes in the corpus callosum at 3 days following injury, compared to vehicle treated animals (b). These
observations were confirmed with counts of the number of reactive astrocytes (e). Positive cell counts were assessed using a one-way
ANOVA followed by Tukey’s post-test. (Sham n = 4, vehicle n = 5, 0.05mg/kg n = 5, 0.5mg/kg n = 4) (p<0.001, compared to vehicle
control animals).
https://doi.org/10.1371/journal.pone.0190449.g004
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Delayed administration of APP96-110 remained efficacious in reducing diffuse axonal
injury. The extent of DAI was determined by counting the number of APP immunopositive
lengths in the corpus callosum (Fig 7). Similar to the 30 minute treatment study, there was a
significant increase in APP immunoreactivity was observed in vehicle control animals at 3
days post-TBI (34±11, n = 8) compared to sham animals (p<0.05, n = 7). This delayed
Fig 5. Representative images showing the degree of neuroinflammation in the corpus callosum at 3 days following diffuse TBI, as
assessed by Iba1 immunoreactivity (a-d). 0.05mg/kg (c) and 0.5mg/kg (d) APP96-110 treated animals demonstrated a profound reduction
in the number of activated microglia in the corpus callosum at 3 days following injury, compared to vehicle treated animals (b). These
observations were confirmed with counts of the number of activated microglia (e). The number of positive Iba1 cells was assessed
individually using a one-way ANOVA followed by Tukey’s post-test. (Sham n = 4, vehicle n = 5, 0.05mg/kg n = 5, 0.5mg/kg n = 4)
(p<0.001, compared to vehicle control animals).
https://doi.org/10.1371/journal.pone.0190449.g005
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treatment with APP96-110 remained efficacious and reduced levels in both the 0.05mg/kg (19
±11, n = 9) and 0.5mg/kg (16±10, n = 9) treatment groups, with DAI not significantly different
to sham animals.
Discussion
Over recent years, a growing body of data has suggested that APP and its derivatives have a
neuroprotective role following TBI [10–12, 24]. This study is the first to examine the neuro-
protective efficacy of APP96-110 following IV administration after TBI.
Posttraumatic administration of APP96-110 IV not only demonstrated noticeable improve-
ments in motor outcome and reductions in axonal injury and neuroinflammation, but impor-
tantly, that APP96-110 remains efficacious when injected up to 5 hours post-TBI. Previous
research has focused solely on intracerebroventricular administration, however, IV adminis-
tration soon after trauma offers clear clinical advantages. Following trauma, ensuing secondary
damage to the BBB facilitates a localized increase in permeability of blood contents into the
brain parenchyma as early as 15 minutes after injury, lasting for up to four to six hours for
large molecules. Permeability for smaller molecules, however, can last up to three to four days
[25, 26]. Whilst this permeability does contribute to the injury process, it also provides a win-
dow of opportunity through which therapeutics may gain entry to the brain [26]. A challenge
for many IV drugs targeting brain injury is the inability to penetrate the BBB and reach the
CNS. However, the ability of IV administered APP96-110 to produce neuroprotective effects
in vivo that were comparable to intracerebroventricular administration, suggests that APP96-
110 can enter the brain following injury in a functional state via the IV route. This has been
Fig 6. Motor outcome illustrating the effect of treatment with 0.05mg/kg and 0.5mg/kg APP96-110 IV at 5 hours
post-TBI. Data was assessed with a two-way repeated measures ANOVA followed by Tukey’s post-test. (Sham n = 7,
vehicle n = 9, 0.05mg/kg n = 10, 0.5mg/kg n = 10, per group). (p<0.001, p<0.01, compared to vehicle control
animals).
https://doi.org/10.1371/journal.pone.0190449.g006
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confirmed with live animal luminescence studies, where APP96-110’s ability to enter the brain
was observed for up to 5 hours post-TBI (unpublished data).
Over the years, a number of experimental therapies have shown promising neuroprotective
efficacy in experimental settings, but subsequently fail to produce similar neuroprotective
Fig 7. Representative images showing the degree of axonal injury in the corpus callosum at 3 days following diffuse TBI (a-d). 0.05mg/
kg (c) and 0.5mg/kg (d) APP960110 treated animals demonstrated a reduced number of APP immunopositive lengths in the corpus
callosum at 3 days following injury, compared to vehicle treated animals (b). These observations were confirmed with counts of the number
of APP immunopositive lengths (e). APP+ lengths were assessed using a one-way ANOVA followed by Tukey’s post-test. (Sham n = 7,
vehicle n = 8, 0.05mg/kg n = 9, 0.5mg/kg n = 9) (p<0.05, compared to sham animals).
https://doi.org/10.1371/journal.pone.0190449.g007
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efficacy in humans [9, 27]. A therapeutic challenge often slowing bench to bedside progress for
TBI is the choice of therapeutic administration time. Research often focuses on an immediate
time point after injury, generally up to one hour post-TBI [3, 8]. However, in a clinical setting,
the time frame between injury and arrival to a trauma unit can often far exceed one hour [3].
Therefore, testing of more clinically relevant time frames is needed to develop TBI treatments
which can be administered by paramedics at the place of injury. APP96-110 demonstrated
clear efficacy for up to 5 hours post-injury, a finding that significantly extends the therapeutic
timeframe for treatment. Its therapeutic efficacy may in fact extend beyond the 5 hour win-
dow, and as such may form the basis of future dose and time response studies using APP96-
110.
The results of this study strengthen previous findings that highlight the considerable neuro-
protective functions of APP and its derivatives in TBI [18]. Following trauma, IV administra-
tion of APP96-110 at 30 minutes resulted in significant improvements in motor outcome over
7 days. Whilst the lowest 0.005mg/kg dose was ineffective, animals treated with the higher
doses no longer displayed significant motor deficits compared to shams at two days after TBI.
Moreover, these doses were able to reduce the currently untreatable DAI, with the 0.05mg/kg
dose of APP96-110 producing a significant decrease in DAI compared to vehicle control ani-
mals at 3 days post-TBI. Importantly, when APP96-110 was administered at 5 hours following
injury, both the 0.05mg/kg and 0.5mg/kg doses remained efficacious at improving motor out-
come, with animals significantly different to vehicle control rats throughout the testing period.
This improvement in outcome was also associated with a reduction in levels of DAI in the cor-
pus callosum at day 3 post-injury compared to vehicle control animals. DAI occurs as a result
of a progressive secondary insult to axons, often leading to prolonged neurological damage
[28–30]. Primary injury often causes considerable axonal stretching, causing localized damage
to the cytoskeleton and subsequent disruption to axoplasmic transport. However, much of the
progression of DAI is secondary in nature, with the disruption of axoplasmic transport leading
to axonal swelling and subsequent axonal disconnection [29, 31], the disruption of sodium
and calcium channels facilitating an influx of ions, and the production of deleterious phospho-
lipases and proteases causing damage to mitochondria and complete axonal separation and
eventually cell death [7, 31]. Injury to this extent is likely to be a major cause of functional defi-
cits, and a key predictor of functional outcome following trauma, particularly in human CNS
conditions.[32] The neuroprotective effects of APP96-110 on DAI, even when administered at
the delayed time of 5 hours post-TBI is important, as this suggests that APP96-110 may reduce
overall injury severity by limiting the progression of axonal damage throughout the secondary
injury cascade, and important finding given that current therapies targeting DAI are lacking.
Whilst axonal injury is an important indicator of injury severity following TBI [7], it is not
the sole factor. A hallmark feature of TBI is neuroinflammation, a significant part of the sec-
ondary injury cascade, which often leads to the prolonged and detrimental neurological injury
and degeneration [33]. As important cells in the neuroinflammatory response, microglia and
astrocytes play a key role in a number of both beneficial and detrimental functions following
CNS injury, including the release of neurotrophic factors, but also both pro- and anti-inflam-
matory cytokines [33]. The impact-acceleration model of diffuse TBI produces wide-spread
axonal damage throughout the brain, particularly in white matter tracts, like the corpus callo-
sum, where axons are abundant [20]. Whilst neuroinflammation can often be observed in cor-
tical regions, in this setting it was assessed within the corpus callosum, as this region
corresponds to the largest area of damage seen following diffuse trauma. Administration of
APP96-110 at 30 minutes post-TBI prevented the profound neuroinflammation associated
with TBI at all doses tested, with numbers of both reactive astrocytes and activated microglia
significantly reduced following APP96-110 treatment. These findings could in part be
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explained by the associated reductions in DAI seen in APP96-110 treated animals, where the
reduction in secondary injury events may reduce the need for neuroinflammation to occur.
This is in contrast to vehicle control animals where secondary injury and DAI was more con-
siderable. Furthermore, the reduction in acute neuroinflammation could represent a pathway
in which APP96-110 treatment acts to ameliorate the motor deficits. As animals were assessed
at day 3, these results only represent the acute neuroinflammatory response, and as such are
not reflective of the long-term progressive nature of posttraumatic neuroinflammation. As
such, investigation into the mechanism through which APP96-110 is able to reduce neuroin-
flammatory events remains an important avenue for further research.
While the use of APP96-110 as a novel and clinically relevant therapeutic agent for TBI has
been clearly demonstrated, the mechanism of action through which APP96-110 exerts these
effects is yet to be fully understood. A key functional domain of sAPPα, of which APP96-110 is
the active region, is its high structural similarity to growth-factor like domains, and its strong
affinity to heparin, particularly to heparin sulfate proteoglycans (HSPGs) [34–36]. The impor-
tance of APP96-110’s affinity for heparin binding for its neuroprotective activity was demon-
strated using an APP96-110 analogue with reduced heparin binding affinity, which in turn
showed no neuroprotective effect in vivo after moderate-severe diffuse TBI [14]. It is thought
that APP96-110 could bind to cell-surface or extracellular matrix bound HSPGs to elicit a
neuritogeneic response [19, 35, 37]. The APP96-110 region contains a β hairpin loop con-
strained by a disulphide bond between cysteines 98 and 105 [36, 37], which has been shown to
be critical for promoting neurite outgrowth from central and peripheral neurons [37–40], as
well as the activation of MAP kinase [41].
Irrespective of the mechanisms of neuroprotection, this study demonstrates that APP96-
110 is efficacious by IV administration for up to 5 hours after TBI and strengthens its potential
as a novel and multifactorial therapeutic agent following trauma. Important next steps for
APP96-110 include enhancing our understanding of its pharmacokinetics to optimize its ther-
apeutic activity, and also identifying its receptor and the signaling pathways it activates, which
will help decipher the molecular mechanisms for APP96-110’s activity. Testing the efficacy of
APP96-110 in other neuronal injury models such as spinal cord injury and ischemia, where
APP expression has been shown to be altered [42, 43], could broaden the therapeutic utility of
APP9-110. As such, further development of APP96-110 as a therapeutic for TBI, and in partic-
ular DAI that currently lacks an efficacious treatment, is warranted. Overall, APP96-110 shows
promise as a novel and clinically relevant treatment option by offering substantial neuropro-
tective and neurotrophic effects towards reducing secondary injury and functional deficits
associated with acute traumatic brain injury.
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